EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Pfizer's enterprise value is $205,122 Mil.
Pfizer's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was $29,983 Mil. Therefore, Pfizer's EV-to-EBITDA for today is 6.84.
The historical rank and industry rank for Pfizer's EV-to-EBITDA or its related term are showing as below:
PFE'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.82 Med: 11.83 Max: 59.08
Current: 6.84
During the past 13 years, the highest EV-to-EBITDA of Pfizer was 59.08. The lowest was 5.82. And the median was 11.83.
PFE's EV-to-EBITDA is ranked better than 79.22% of 717
companies
in the Drug Manufacturers industry
Industry Median: 13.76
vs PFE: 6.84
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2023-09-24), Pfizer's stock price is $32.69.
Pfizer's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $3.760. Therefore, Pfizer's PE Ratio for today is 8.69.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Pfizer EV-to-EBITDA Historical Data
The historical data trend for Pfizer's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Pfizer Annual Data
Trend
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
EV-to-EBITDA
23.48
13.24
17.43
10.98
7.32
Pfizer Quarterly Data
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
EV-to-EBITDA
7.78
6.22
7.32
6.37
7.60
Competitive Comparison
For the Drug Manufacturers - General subindustry, Pfizer's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pfizer EV-to-EBITDA Distribution
For the Drug Manufacturers industry and Healthcare sector, Pfizer's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Pfizer's EV-to-EBITDA falls in comparison to its industry or sector. The grey bar indicates the EV-to-EBITDA's extreme value range as defined by GuruFocus.
Pfizer's current Enterprise Value is $205,122 Mil.
Pfizer's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $29,983 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pfizer (NYSE:PFE) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Pfizer's share price for today is $32.69.
Pfizer's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.760.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Pfizer's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
0.16(0.49%) Volume: 28,446,928 11:09PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
PFE has been successfully added to your 
